AIDS Vaccine 2009 - Abstracts

Regular Submission Abstract and Scholarship Dispositions

Abstract and scholarship disposition notices have been sent out. If you did not receive an email regarding the status of your abstract submission or scholarship application, please email Karly Kopra at Karly@ConferenceSolutionsInc.com.

Late Breaker Submission Guidelines

The Conference will be accepting late breaker abstract submissions from 6 July - 20 August 2009.

Individuals submitting abstracts agree that if their abstract is accepted, they will attend the meeting and present their abstract as scheduled. The presenting author should be able to answer substantive questions about all aspects of their study.

Once an abstract has been accepted and scheduled, it cannot be withdrawn. Authors agree to have the abstract published in the Conference Abstract Book and as a supplement to a scientific journal related to the field.

Topics

  • Acute HIV/SIV infection
  • Adjuvants
  • Animal Models
  • B Cell Immunity & Neutralizing Antibodies
  • B Cell vaccine concepts & design
  • Clinical Trial Site Development
  • HIV transmission
  • Host Genetic Factors
  • Immune Escape
  • Innate Immunity
  • Mucosal Immunity
  • Novel Immunogens/Inserts
  • Prevention Strategies
  • Prophylactic Vaccine Trials
  • Social/Ethical/Access/Regulatory issues
  • T cell immunity
  • T cell vaccine concepts & design
  • Therapeutic vaccine
  • Vaccine concepts & design
  • Viral diversity

On-Line Abstract Submission

Abstracts must be submitted via the online submission system on this web site. Submitters will be prompted through the electronic submission process.

Click here to view a checklist of the information needed for abstract submission. Please carefully review the abstract prior to its submission. Note that if an abstract has been entered but the “Save and Complete” button has not been clicked, it is not considered submitted and will not be reviewed. Edits to the abstract (other than designating a different category) may be made online after submission up until the deadline of 12:00 Midnight PDT, 20 August 2009. Editing a submitted abstract requires use of the abstract ID number that you will receive by email after you have completed the submission process (see Notification and Correspondence below). You may only have one incomplete abstract at a time. You cannot start a second abstract without completing and submitting the first.

The late breaker submission period is now closed.

Published Abstracts

Accepted abstracts will be published in the AIDS Vaccine 2009 Abstract Book and distributed to registrants. Abstracts will also be published as a supplement to a scientific journal related to the field.

Copyright and Webcast Policy

By submitting an abstract, authors and co-authors transfer any copyrights and grant permission to AIDS Vaccine 2009 to audio/video record oral presentations.

Abstract Selection Process

Abstract submissions will be peer reviewed by the Conference Organizers and members of the Scientific Organizing Committee. To minimize subjectivity in the scoring process, any reviewer with a conflict of interest (as defined by NIH rules, e.g., co-authorship, financial interest, or scientific/personal conflict with the authors that could affect objectivity of scoring) will be excluded from scoring or discussing the abstract in question. In the final rankings, mean score and standard deviation will be calculated, and the reviewers' scores will be anonymous. Abstract acceptance is based upon abstract quality, the potential significance of the observations, and the rigor with which the scientific methods were applied. Further, the Conference Organizers consider thematic balance in determining which abstracts will be presented orally.

Poster Specifications

Poster presentation space is a portrait poster board with the dimensions of 118 cm X 95 cm. Velcro must be used to adhere the poster to the poster board. All posters must remain up for the duration of the Conference.

For complete poster presentation guidelines, please click here.